Table 6A - New
Diagnosis Codes
|
Diagnosis Code |
Description |
CC |
MDC |
MS-DRG |
|
040.41 |
Infant botulism |
Y CC |
15 18 |
7911
, 7931 867,
868, 869 |
|
040.42 |
Wound botulism |
Y CC |
18 |
867,
868, 869 |
|
058.10 |
Roseola infantum, unspecified |
N |
15 18 |
7911,
7931 865,
866 |
|
058.11 |
Roseola infantum due to human herpesvirus 6 |
N |
15 18 |
7911,
7931 865,
866 |
|
058.12 |
Roseola infantum due to human herpesvirus 7 |
N |
15 18 |
7911,
7931 865,
866 |
|
058.21 |
Human herpesvirus 6 encephalitis |
Y MCC |
1 15 25 |
23,24,97,
98, 99 7911, 7931 974,
975, 976 |
|
058.29 |
Other human herpesvirus encephalitis |
Y MCC |
1 15 25 |
23,
24,97, 98, 99 7911,
7931 974,
975, 976 |
|
058.81 |
Human herpesvirus 6 infection |
N |
9 |
606,
607 |
|
058.82 |
Human herpesvirus 7 infection |
N |
9 |
606,
607 |
|
058.89 |
Other human herpesvirus infection |
N |
9 |
606,
607 |
|
079.83 |
Parvovirus B19 |
Y CC |
18 |
865,
866 |
|
200.30 |
Marginal zone lymphoma, unspecified site, extranodal and solid organ sites |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840, 841, 842 974,
975, 976 |
|
200.31 |
Marginal zone lymphoma, lymph nodes of head, face, and neck |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840, 841, 842 974,
975, 976 |
|
200.32 |
Marginal zone lymphoma, intrathoracic lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825,840, 841, 842 974,
975, 976 |
|
200.33 |
Marginal zone lymphoma, intraabdominal lymph
nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840, 841, 842 974,
975, 976 |
|
200.34 |
Marginal zone lymphoma, lymph nodes of axilla and upper limb |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840, 841, 842 974,
975, 976 |
|
200.35 |
Marginal zone lymphoma, lymph nodes of inguinal region and lower limb |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840, 841, 842 974,
975, 976 |
|
200.36 |
Marginal zone lymphoma, intrapelvic lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840, 841, 842 974,
975, 976 |
|
200.37 |
Marginal zone lymphoma, spleen |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.38 |
Marginal zone lymphoma, lymph nodes of multiple sites |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840, 841, 842 974,
975, 976 |
|
200.40 |
Mantle cell lymphoma, unspecified site, extranodal and solid organ sites |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840, 841, 842 974,
975, 976 |
|
200.41 |
Mantle cell lymphoma, lymph nodes of head, face, and neck |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840, 841,842 974,
975, 976 |
|
200.42 |
Mantle cell lymphoma, intrathoracic lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840, 841, 842 974,
975, 976 |
|
200.43 |
Mantle cell lymphoma, intra-abdominal lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840, 841, 842 974,
975, 976 |
|
200.44 |
Mantle cell lymphoma, lymph nodes of axilla and upper limb |
Y CC |
17 25 |
820,821,
822, 823, 824, 825, 840, 841, 842 974,
975, 976 |
|
200.45 |
Mantle cell lymphoma,lymph nodes of inguinal region and lower limb |
Y CC |
17 25 |
820,821,
822, 823, 824, 825, 840, 841, 842 974,
975, 976 |
|
200.46 |
Mantle cell lymphoma, intrapelvic lymph nodes |
Y CC |
17 25 |
820,821,
822, 823, 824, 825, 840,
841,842 974,
975, 976 |
|
200.47 |
Mantle cell lymphoma, spleen |
Y CC |
17 25 |
820,821,
822, 823, 824, 825, 840, 841, 842 974,
975, 976 |
|
200.48 |
Mantle cell lymphoma, lymph nodes of multiple sites |
Y CC |
17 25 |
820,821,
822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.50 |
Primary central nervous system lymphoma, unspecified site, extranodal and solid organ sites |
Y CC |
17 25 |
820,821,
822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.51 |
Primary central nervous system lymphoma, lymph nodes of head, face, and neck |
Y CC |
17 25 |
820,821,
822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.52 |
Primary central nervous system lymphoma, intrathoracic lymph nodes |
Y CC |
17 25 |
820,821,
822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.53 |
Primary central nervous system lymphoma, intra-abdominal lymph nodes |
Y CC |
17 25 |
820,821,
822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.54 |
Primary central nervous system lymphoma, lymph nodes of axilla and upper limb |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.55 |
Primary central nervous system lymphoma, lymph nodes of inguinal region and lower limb |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.56 |
Primary central nervous system lymphoma, intrapelvic lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.57 |
Primary central nervous system lymphoma, spleen |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.58 |
Primary central nervous system lymphoma, lymph nodes of multiple sites |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.60 |
Anaplastic large cell lymphoma, unspecified site, extranodal and solid organ sites |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.61 |
Anaplastic large cell lymphoma, lymph nodes of head, face, and neck |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.62 |
Anaplastic large cell lymphoma, intrathoracic lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.63 |
Anaplastic large cell lymphoma, intra-abdominal lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.64 |
Anaplastic large cell lymphoma, lymph nodes of axilla and upper limb |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.65 |
Anaplastic large cell lymphoma, lymph nodes of inguinal region and lower limb |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.66 |
Anaplastic large cell lymphoma, intrapelvic lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.67 |
Anaplastic large cell lymphoma, spleen |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.68 |
Anaplastic large cell lymphoma, lymph nodes of multiple sites |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.70 |
Large cell lymphoma, unspecified site, extranodal and solid organ sites |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.71 |
Large cell lymphoma, lymph nodes of head, face, and neck |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841,842 974,
975, 976 |
|
200.72 |
Large cell lymphoma, intrathoracic lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.73 |
Large cell lymphoma, intra-abdominal lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841,842 974,
975, 976 |
|
200.74 |
Large cell lymphoma, lymph nodes of axilla and upper limb |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841,842 974,
975, 976 |
|
200.75 |
Large cell lymphoma, lymph nodes of inguinal region and lower limb |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.76 |
Large cell lymphoma, intrapelvic lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.77 |
Large cell lymphoma, spleen |
Y CC |
17 25 |
820,821,
822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
200.78 |
Large cell lymphoma, lymph nodes of multiple sites |
Y CC |
17 25 |
820,821,
822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
202.70 |
Peripheral T cell lymphoma, unspecified site, extranodal and solid organ sites |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
202.71 |
Peripheral T cell lymphoma, lymph nodes of head, face, and neck |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
202.72 |
Peripheral T cell lymphoma, intrathoracic lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
202.73 |
Peripheral T cell lymphoma, intra-abdominal lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
202.74 |
Peripheral T cell lymphoma, lymph nodes of axilla and upper limb |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
202.75 |
Peripheral T cell lymphoma, lymph nodes of inguinal region and lower limb |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
202.76 |
Peripheral T cell lymphoma, intrapelvic lymph nodes |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
202.77 |
Peripheral T cell lymphoma, spleen |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
202.78 |
Peripheral T cell lymphoma, lymph nodes of multiple sites |
Y CC |
17 25 |
820,
821, 822, 823, 824, 825, 840,
841, 842 974,
975, 976 |
|
|
|
|
|
|
|
233.30 |
Carcinoma in situ, unspecified female genital organ |
N |
13 |
739,
740, 741, 744, 745, 754, 755, 756 |
|
233.31 |
Carcinoma in situ,vagina |
N |
13 |
739,
740, 741, 744, 745, 754, 755, 756 |
|
233.32 |
Carcinoma in situ,vulva |
N |
13 |
739,
740, 741, 744, 745, 754, 755, 756 |
|
233.39 |
Carcinoma in situ,other female genital organ |
N |
13 |
739,
740, 741, 744, 745, 754, 755, 756 |
|
255.41 |
Glucocorticoid deficiency |
Y CC |
10 |
643,
644, 645 |
|
255.42 |
Mineralocorticoid deficiency |
Y CC |
10 |
643,
644, 645 |
|
258.01 |
Multiple endocrine neoplasia [MEN] type I |
N |
10 |
643,
644, 645 |
|
258.02 |
Multiple endocrine neoplasia [MEN] type IIA |
N |
10 |
643,
644, 645 |
|
258.03 |
Multiple endocrine neoplasia [MEN] type IIB |
N |
10 |
643,
644, 645 |
|
284.81 |
Red cell aplasia (acquired)(adult)(with thymoma) |
Y MCC |
16 25 |
808,
809, 810 977 |
|
284.89 |
Other specified aplastic anemias |
Y MCC |
16 25 |
808,
809, 810 977 |
|
288.66 |
Bandemia |
N |
16 |
814,
815, 816 |
|
315.34 |
Speech
and language developmental delay due to hearing loss |
N |
19 |
886 |
|
331.5 |
Idiopathic normal pressure hydrocephalus (INPH) |
Y CC |
1 |
56,
57 |
|
359.21 |
Myotonic muscular dystrophy |
N |
1 |
91,
92, 93 |
|
359.22 |
Myotonia congenita |
N |
1 |
91,
92, 93 |
|
359.23 |
Myotonic chondrodystrophy |
N |
1 |
91,
92, 93 |
|
359.24 |
Drug induced myotonia |
N |
1 |
91,
92, 93 |
|
359.29 |
Other specified myotonic disorder |
N |
1 |
91,
92, 93 |
|
364.81 |
Floppy iris syndrome |
N |
2 |
124,
125 |
|
364.89 |
Other disorders of iris and ciliary body |
N |
2 |
124,
125 |
|
388.45 |
Acquired auditory processing disorder |
N |
19 |
886 |
|
389.05 |
Conductive hearing loss, unilateral |
N |
3 |
154,
155, 156 |
|
389.06 |
Conductive hearing loss, bilateral |
N |
3 |
154,
155, 156 |
|
389.13 |
Neural hearing loss, unilateral |
N |
3 |
154,
155, 156 |
|
389.17 |
Sensory hearing loss, unilateral |
N |
3 |
154,
155, 156 |
|
389.20 |
Mixed hearing loss, unspecified |
N |
3 |
154,
155, 156 |
|
389.21 |
Mixed hearing loss, unilateral |
N |
3 |
154,
155, 156 |
|
389.22 |
Mixed hearing loss, bilateral |
N |
3 |
154,
155, 156 |
|
414.2 |
Chronic total occlusion of coronary artery |
N |
5 |
302,
303 |
|
415.12 |
Septic pulmonary embolism |
Y MCC |
4 15 |
175,176 7911,
7931 |
|
423.3 |
Cardiac tamponade |
Y CC |
5 |
314,
315, 316 |
|
440.4 |
Chronic total occlusion of artery of the extremities |
N |
5 |
299,
300, 301 |
|
449 |
Septic arterial embolism |
Y CC |
5 15 |
299,
300, 301 7911,
7931 |
|
488 |
Influenza due to identified avian influenza virus |
N |
3 |
152,
153 |
|
525.71 |
Osseointegration failure of dental implant |
N |
PRE3 |
11,
12, 13 157,
158, 159 |
|
525.72 |
Post-osseointegration biological failure of dental implant
|
N |
PRE 3 |
11,
12, 13 157,
158, 159 |
|
525.73 |
Post-osseointegration mechanical failure of dental implant |
N |
PRE 3 |
11,
12, 13 157,
158, 159 |
|
525.79 |
Other endosseous dental implant failure |
N |
PRE 3 |
11,
12, 13 157,
158, 159 |
|
569.43 |
Anal sphincter tear (healed) (old) |
N |
6 |
393,
394, 395 |
|
624.01 |
Vulvar intraepithelial neoplasia I [VIN I] |
N |
13 |
742, 743, 760, 761 |
|
624.02 |
Vulvar intraepithelial neoplasia II [VIN II] |
N |
13 |
742, 743, 760, 761 |
|
624.09 |
Other dystrophy of vulva |
N |
13 |
742, 743, 760, 761 |
|
664.60 |
Anal sphincter tear complicating delivery, not associated with third-degree perineal laceration,unspecified as to episode of care or not applicable |
N |
14 |
765,
766, 767, 768, 774, 775 |
|
664.61 |
Anal sphincter tear complicating delivery, not associated with third-degree perineal laceration,delivered, with or without mention of antepartum condition |
Y CC |
14 |
765,
766, 767, 768, 774,775 |
|
664.64 |
Anal sphincter tear complicating delivery, not associated with third-degree perineal laceration,postpartum condition or complication |
Y CC |
14 |
769,
776 |
|
733.45 |
Aseptic necrosis of bone, jaw |
Y CC |
8 |
553,
554 |
|
787.20 |
Dysphagia, unspecified |
N |
6 |
391,
392 |
|
787.21 |
Dysphagia, oral phase |
N |
6 |
391,
392 |
|
787.22 |
Dysphagia, oropharyngeal phase |
N |
6 |
391,
392 |
|
787.23 |
Dysphagia, pharyngeal phase |
N |
6 |
391,
392 |
|
787.24 |
Dysphagia, pharyngoesophageal phase |
N |
6 |
391,
392 |
|
787.29 |
Other dysphagia |
N |
6 |
391,
392 |
|
789.51 |
Malignant ascites |
Y CC |
23 |
947,
948 |
|
789.59 |
Other ascites |
Y CC |
23 |
947,
948 |
|
999.31* |
Infection due to central venous catheter |
Y CC |
5 |
314,315,316 |
|
999.39* |
Infection following other infusion, injection, transfusion, or vaccination |
Y CC |
15 18 |
7911,7931 856,
857, 858, 867, 868, 869 |
|
V12.53 |
Personal history of sudden cardiac arrest |
N |
23 |
951 |
|
V12.54 |
Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits |
N |
23 |
951 |
|
V13.22 |
Personal history of cervical dysplasia |
N |
17 |
843,
844, 845 |
|
V16.52 |
Family history of malignant neoplasm,bladder |
N |
23 |
951 |
|
V17.41 |
Family history of sudden cardiac death (SCD) |
N |
23 |
951 |
|
V17.49 |
Family history of other cardiovascular diseases |
N |
23 |
951 |
|
V18.11 |
Family history of multiple endocrine neoplasia [MEN] syndrome |
N |
23 |
951 |
|
V18.19 |
Family history of other endocrine and metabolic diseases |
N |
23 |
951 |
|
V25.04 |
Counseling and instruction in natural family planning to avoid pregnancy |
N |
23 |
951 |
|
V26.41 |
Procreative counseling and advice using natural family planning |
N |
23 |
951 |
|
V26.49 |
Other procreative management, counseling and advice |
N |
23 |
951 |
|
V26.81 |
Encounter for assisted reproductive fertility procedure cycle |
N |
23 |
951 |
|
V26.89 |
Other specified procreative management |
N |
23 |
951 |
|
V49.85 |
Dual sensory impairment |
N |
23 |
951 |
|
V68.01 |
Disability examination |
N |
23 |
951 |
|
V68.09 |
Other issue of medical certificates |
N |
23 |
951 |
|
V72.12 |
Encounter for hearing conservation and treatment |
N |
15 23 |
7952 951 |
|
V73.81 |
Special screening examination, Human papillomavirus (HPV) |
N |
23 |
951 |
|
V84.81 |
Genetic susceptibility to multiple endocrine neoplasia [MEN] |
N |
23 |
951 |
|
V84.89 |
Genetic susceptibility to other disease |
N |
23 |
951 |
MCC – Major
Complication or Comorbidity in MS-DRGs.
New codes
629.82, 629.83, 629.84 and V17.40 that were listed in the proposed rule have
been deleted.
They will not be
implemented on October 1, 2007.
1 Secondary
diagnosis of major problem.
2 On
“Only secondary diagnosis” list.
These
diagnosis codes were discussed at the March 22-23, 2007 ICD-9-CM Coordination
and
Maintenance
Committee meeting and were not finalized in time to include in the proposed
rule.
They
will be implemented on October 1, 2007.
Table 6B - New Procedure
Codes
|
Procedure Code |
Description |
OR |
MDC |
MS-DRG |
|
00.19 |
Disruption of blood brain barrier via infusion [BBBD] |
N |
|
|
|
00.94* |
Intra-operative neurophysiologic monitoring |
N
|
|
|
|
01.10 |
Intracranial pressure
monitoring |
N |
|
|
|
01.16 |
Intracranial oxygen monitoring |
N |
|
|
|
01.17 |
Brain temperature monitoring |
N |
|
|
|
07.83* |
Thoracoscopic partial excision of thymus |
Y |
1 4 10 16 17 21 24 |
40,
41, 42 163,
164, 165 628,
629, 630 802,
803, 804 820,
821, 822, 826, 827,
828 907,
908, 909 957,
958, 959 |
|
07.84* |
Thoracoscopic total excision of thymus |
Y |
1 4 10 16 17 21 24 |
40,
41, 42 163,
164, 165 628,
629, 630 802,
803, 804 820,
821, 822, 826, 827,
828 907,
908, 909 957,
958, 959 |
|
07.95* |
Thoracoscopic incision of thymus |
Y |
1 4 10 16 17 21 24 |
40,
41, 42 163,
164, 165 628,
629, 630 802,
803, 804 820,
821, 822, 826, 827,
828 907,
908, 909 957,
958, 959 |
|
07.98* |
Other and unspecified thoracoscopic operations on thymus |
Y |
1 4 10 16 17 21 24 |
40,
41, 42 163,
164, 165 628,
629, 630 802,
803, 804 820,
821, 822, 826, 827,
828 907,
908, 909 957,
958, 959 |
|
32.20* |
Thoracoscopic excision of lesion or tissue of lung |
Y |
4 17 21 24 |
163,
164, 165 820,
821, 822, 826, 827,
828 907,
908, 909 957,
958, 959 |
|
32.30* |
Thoracoscopic segmental resection of lung |
Y |
4 17 21 24 |
163,
164, 165 820,
821, 822, 826, 827,
828 907,
908, 909 957,
958, 959 |
|
32.39* |
Other and unspecified segmental resection of lung |
Y |
4 17 21 2 |
163,
164, 165 820,
821, 822, 826, 827,
828 907,
908, 909 957,
958, 959 |
|
32.41 |
Thoracoscopic lobectomy of
lung |
Y |
4 21 24 |
163,
164, 165 907,
908, 909 957,
958, 959 |
|
32.49 |
Other lobectomy of lung |
Y |
4 21 24 |
163,
164, 165 907,
908, 909 957,
958, 959 |
|
32.50* |
Thoracoscopic pneumonectomy |
Y |
4 21 24 |
163,164,165 907,
908, 909 957,
958, 959 |
|
32.59* |
Other and unspecified pneumonectomy |
Y |
4 21 24 |
163,
164, 165 907,
908, 909 957,
958, 959 |
|
33.20 |
Thoracoscopic lung biopsy |
Y |
4 5 8 11 17 |
166, 167, 168 264 515,
516, 517 673,
674, 675 823,
824, 825, 829, 830 |
|
34.06 |
Thoracoscopic drainage of pleural cavity |
Y |
4 |
166,
167, 168 |
|
34.20 |
Thoracoscopic pleural biopsy |
Y |
4 |
166,
167, 168 |
|
34.52 |
Thoracoscopic decortication of lung |
Y |
4 17 21 24 |
163,
164, 165 820,
821, 822,826, 827, 828 907,
908, 909 957,
958, 959 |
|
50.13* |
Transjugular liver biopsy |
N |
|
|
|
50.14* |
Laparoscopic liver
biopsy |
Y |
6 7 9 11 16 17 21 24 |
356,
357, 358 420,
421, 422 579,
580, 581 673,
674, 675 802,
803, 804 820,
821, 822, 826, 827,
828 907,
908, 909 957,
958, 959 |
|
70.53 |
Repair of cystocele and rectocele with graft or
prosthesis |
Y |
6 11 13 |
329,
330, 331 653,
654, 655 748 |
|
70.54 |
Repair of cystocele with graft or prosthesis |
Y |
11 13 |
662,
663, 664 748 |
|
70.55 |
Repair of rectocele with graft or prosthesis |
Y |
6 13 |
329,
330, 331 748 |
|
70.63 |
Vaginal construction with graft or prosthesis |
Y |
13 |
748 |
|
70.64 |
Vaginal reconstruction with graft or prosthesis |
Y |
13 21 24 |
748 907,
908, 909 957,
958, 959 |
|
70.78 |
Vaginal suspension and fixation with graft or prosthesis |
Y |
11 13 |
662,
663, 664 748 |
|
70.93 |
Other operations on cul-de-sac with graft or prosthesis |
Y |
13 |
746,
747 |
|
70.94 |
Insertion of biological graft |
N |
|
|
|
70.95 |
Insertion of synthetic graft or prosthesis |
N |
|
|
|
84.80* |
Insertion or replacement of interspinous process device(s) |
Y |
1 8 21 24 |
28,
29, 30 490 907,
908, 909 957,
958, 959 |
|
84.81* |
Revision of interspinous process device(s) |
Y |
8 21 24 |
515,
516, 517 907,
908, 909 957,
958, 959 |
|
84.82* |
Insertion or replacement of pedicle-based dynamic stabilization device(s) |
Y |
1 8 21 24 |
28,
29, 30 490 907,
908, 909 957,
958, 959 |
|
84.83* |
Revision of pedicle-based dynamic stabilization device(s) |
Y |
8 21 24 |
515,
516, 517 907,
908, 909 957,
958, 959 |
|
84.84* |
Insertion or replacement of facet replacement
device(s) |
Y |
1 8 21 24 |
28,
29, 30 490 907,
908, 909 957,
958, 959 |
|
84.85* |
Revision
of facet replacement device(s) |
Y |
8 21 24 |
515,
516, 517 907,
908, 909 957,
958, 959 |
|
88.59
|
Intra-operative
fluorescence vascular angiography |
N |
|
|
|
92.41* |
Intra-operative electron radiation therapy |
N |
|
|
*These
procedure codes were discussed at the March 22-23, 2007 ICD-9-CM Coordination
and
Maintenance
Committee meeting and were not finalized in time to include in the proposed
rule.
They
will be implemented on October 1, 2007.
Table 6C – Invalid
Diagnosis Codes
|
Diagnosis Code |
Description |
CC |
MDC |
CMS DRG |
|
233.3 |
Carcinoma in situ,other and unspecified female genital organs |
N |
13 |
354,
355, 363, 366, 367 |
|
255.4 |
Corticoadrenal insufficiency |
Y |
10 |
300,
301 |
|
258.0 |
Polyglandular activity in
multiple endocrine adenomatosis |
N |
10 |
300,
301 |
|
284.8 |
Other specified aplastic
anemias |
Y |
16 25 |
574 490 |
|
359.2 |
Myotonic disorders |
N |
1 |
34,
35 |
|
364.8 |
Other disorders of iris and ciliary body |
N |
2 |
46,
47, 48 |
|
389.2 |
Mixed conductive and sensorineural hearing loss |
N |
3 |
73,
74 |
|
624.0 |
Dystrophy of vulva |
N |
13 |
358,
359, 369 |
|
787.2 |
Dysphagia |
N |
6 |
182,
183, 184 |
|
789.5 |
Ascites |
Y |
23 |
463,
464 |
|
999.3* |
Complications of medical care, not elsewhere classified, Other infection |
Y |
15 18 |
3871,
3891 423,
579 |
|
V17.4 |
Family history of other cardiovascular diseases |